Evidence map›Paper›PMID 38741123›Full record

ArticleJournal of nanobiotechnology2024

Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN.

Yanzi Sun, Yishu Wang, Chunyan Liu, Yingshuang Huang, Qiulin Long, Caoyun Ju, Can Zhang, Yijun Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yanzi SunState Key Laboratory of Natural Medicines and Laboratory of Chemical Biology, China Pharmaceutical University, 639 Longmian Ave, Nanjing, 211198, Jiangsu, China.
Yishu WangState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Chunyan LiuState Key Laboratory of Natural Medicines and Laboratory of Chemical Biology, China Pharmaceutical University, 639 Longmian Ave, Nanjing, 211198, Jiangsu, China.
Yingshuang HuangState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Qiulin LongState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Caoyun JuState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. jucaoyun@cpu.edu.cn.
Can ZhangState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. zhangcan@cpu.edu.cn.
Yijun ChenState Key Laboratory of Natural Medicines and Laboratory of Chemical Biology, China Pharmaceutical University, 639 Longmian Ave, Nanjing, 211198, Jiangsu, China. yjchen@cpu.edu.cn.

Funding

Key Research and Development Project of Guangdong Province 2022B1111070004the Double "First-Class" University Project CPU2022QZ08the National Key R&D Program of China 2018YFA0902000the Project Program of the State Key Laboratory of Natural Medicines, China Pharmaceutical University SKLNMZZ202201
6 · The paper itself

Abstract

Tyrosine kinase inhibitors have been the standard treatment for patients with Philadelphia chromosome-positive (Ph

Indexed as

Fusion Proteins, bcr-ablNanoparticlesAnimalsApoptosisCell Line, TumorCell ProliferationGene SilencingGenetic TherapyHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMiceMice, Inbred BALB CMuscle ProteinsNEDD8 ProteinRNA, Small InterferingUbiquitin-Protein LigasesFusion Proteins, bcr-ablMuscle ProteinsNEDD8 ProteinNEDD8 protein, humanperipheral membrane protein 43KRNA, Small InterferingUbiquitin-Protein LigasesCD79BLipid nanoparticlesPh+ leukemiaRAPSYNscFvsiRNA

Identifiers

PMID38741123
PMCPMC11089668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.